glp gip glucagon & cagrilintide Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit GLP-1, GIP and glucagon receptor

Gastrointestinal adverse effects represent the most commonly observed side effects of Semaglutide / Cyanocobalamin Injection, occurring in a substantial proportion of patients, particularly during the initial weeks of treatment or following dose escalations

A 2025 Nature Communications paper mapped the binding to the disordered transactivation domain of p53, adding structural detail to how FOXO4-DRI engages its target

What's more interesting, the reading or the scale

HUBERMAN: My whole purpose in doing this episode is to highlight how these different molecules ought to work, how they've been shown to work in animal models, and therefore how they might be working in humans